Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) Short Interest Increased By 10.97%

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment decreased to 1.17 in 2019 Q2. Its down 0.32, from 1.49 in 2019Q1. It is negative, as 36 investors sold Jazz Pharmaceuticals plc shares while 105 reduced holdings. 52 funds opened positions while 113 raised stakes. 50.63 million shares or 4.18% more from 48.59 million shares in 2019Q1 were reported.
State Bank Of New York Mellon accumulated 956,204 shares or 0.04% of the stock. Asset Mngmt One Ltd owns 28,369 shares or 0.02% of their US portfolio. Macquarie Grp stated it has 14,300 shares or 0% of all its holdings. Smith Asset Mngmt L P has 0.73% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 153,970 shares. Caisse De Depot Et Placement Du Quebec holds 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 11,500 shares. Pnc Fincl Services Grp owns 14,992 shares for 0% of their portfolio. Korea Invest Corp holds 0.06% or 90,400 shares. Rice Hall James And Associates Ltd Company invested in 0.17% or 35,840 shares. 41,500 were accumulated by Omers Administration. United Services Automobile Association owns 38,725 shares for 0.01% of their portfolio. Moreover, Hbk Sorce Advisory Limited Liability has 0.07% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 2,292 shares. State Of Wisconsin Invest Board owns 0.02% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 49,818 shares. Fernwood Mgmt Ltd Liability Corporation invested 0.13% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). The United Kingdom-based Barclays Public Ltd Com has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Principal Financial Incorporated invested in 6,632 shares.

The stock of Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) registered an increase of 10.97% in short interest. JAZZ’s total short interest was 2.24M shares in October as published by FINRA. Its up 10.97% from 2.02M shares, reported previously. With 499,000 shares average volume, it will take short sellers 5 days to cover their JAZZ’s short positions. The short interest to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 4.08%.

The stock increased 0.60% or $0.71 during the last trading session, reaching $118.67. About 369,908 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 19.23% since October 12, 2018 and is downtrending. It has underperformed by 19.23% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $6.72 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 10.76 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 4 analysts covering Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Jazz Pharmaceuticals plc – Ordinary Shares has $20800 highest and $14200 lowest target. $165.50’s average target is 39.46% above currents $118.67 stock price. Jazz Pharmaceuticals plc – Ordinary Shares had 5 analyst reports since May 8, 2019 according to SRatingsIntel. On Wednesday, May 8 the stock rating was maintained by Mizuho with “Neutral”. The company was downgraded on Wednesday, August 21 by Piper Jaffray. BMO Capital Markets maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Wednesday, May 8 with “Outperform” rating.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Nasdaq.com which released: “Top Stock Reports for Microsoft, Royal Dutch Shell & IBM – Nasdaq” on October 09, 2019, also Finance.Yahoo.com with their article: “Here’s Why I Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Is An Interesting Stock – Yahoo Finance” published on September 07, 2019, Prnewswire.com published: “Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update – PRNewswire” on September 18, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Fool.com and their article: “3 Incredibly Cheap Healthcare Stocks – The Motley Fool” published on July 14, 2019 as well as Finance.Yahoo.com‘s news article titled: “TowerJazz Announces the Availability of its Newly Released Advanced Stacked BSI Hybrid Bonding Technology – Yahoo Finance” with publication date: September 25, 2019.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.